EUVIMEDEUVIMED entdecken
Open Access

The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression

Oscar E Zazueta iD, Mercedes C Becerra, Jerome T Galea, Roger I Calderon, Carmen Contreras, Chuan-Chin Huang, Judith Jimenez iD, Leonid W Lecca iD, Rosa M Yataco, Zibiao Zhang, Megan B Murray iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Oscar E Zazueta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Isoniazid, Antitubercular Agents, Tuberculosis, Tuberculosis, Pulmonary. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Center for Excellence in Translational Research, National Institute of Allergy and Infectious Diseases, Tuberculosis Research Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB) causes major morbidity and mortality among children worldwide. Isoniazid preventive therapy (IPT) protects against progression to TB disease, but its effect on preventing new TB infection remains uncertain.

Methods

We conducted a longitudinal cohort study in Lima, Peru, enrolling adults with microbiologically confirmed pulmonary TB and their household contacts (HHCs). We assessed HHCs at baseline and 6 months for TB infection using tuberculin skin testing (TST) and for TB disease through clinical evaluation. We assessed 2 outcomes in relation to IPT initiation: TB infection among HHCs under 5 years of age, indicated by an increase in TST induration of ≥6 mm from baseline to 6 months, and progression to TB disease among HHCs of all ages, diagnosed between 15 days and 12 months after enrollment.

Results

Among 666 under-5-year-olds included assessed for TST conversion, 361 (54.2%) had initiated IPT. Overall, 103 (15.5%) converted at 6 months; IPT initiation was not associated with conversion (adjusted OR 1.01; 95% CI, .64–1.59). Index participant cavitary disease was associated with an increased risk of conversion. In contrast, IPT initiation was associated with reduced risk of progression to TB disease among 14 032 HHCs of all ages (adjusted HR 0.45; 95% CI, .32–.64) with more pronounced efficacy among under-5 seconds (adjusted HR 0.19; 95% CI, .10–.36).

Conclusions

Isoniazid preventive therapy was not associated with reduced TST conversion among children under 5 years, but it was strongly associated with reduced progression to TB disease among HHCs of all ages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidAntitubercular AgentsTuberculosisTuberculosis, PulmonaryHumansDisease ProgressionChild, PreschoolMaleFemaleLongitudinal StudiesPeruInfantTuberculin TestAdultYoung AdultAdolescentInfant, Newborn

Stichwörter der Autor:innen

Peruchildrencohort studyisoniazid preventive therapytuberculosis

Substanzen

IsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • School of Social Work, University of South Florida, Tampa, Florida, USA.
  • Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Peru.
  • Socios En Salud, Lima, Peru.
  • Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Oscar E Zazueta, Judith Jimenez, Leonid W Lecca, Megan B Murray

Förderung

  • Center for Excellence in Translational Research
  • National Institute of Allergy and Infectious Diseases
  • Tuberculosis Research Unit
  • NIAID NIH HHS
  • NIH

Zitieren

APA

Zazueta, O. E., Becerra, M. C., Galea, J. T., Calderon, R. I., Contreras, C., Huang, C. C., Jimenez, J., Lecca, L. W., Yataco, R. M., Zhang, Z., & Murray, M. B. (2026). The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag483

Vancouver

Zazueta OE, Becerra MC, Galea JT, Calderon RI, Contreras C, Huang CC, et al. The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag483

BibTeX
@article{Zazueta2026,
  author = {Zazueta, Oscar E and Becerra, Mercedes C and Galea, Jerome T and Calderon, Roger I and Contreras, Carmen and Huang, Chuan-Chin and Jimenez, Judith and Lecca, Leonid W and Yataco, Rosa M and Zhang, Zibiao and Murray, Megan B},
  title = {The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag483}
}
Kostenlos starten →